Visualitzant O - Articles científics per títol

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Wainberg, Zev; Melisi, Davide; Pazo-Cid, Roberto A.; Chandana, Sreenivasa R; DE LA FOUCHARDIERE, CHRISTELLE; Macarulla, Teresa (Elsevier, 2023-10-07)

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial

Bekaii-Saab, Tanios S; Okusaka, Takuji; Goldstein, David; Ueno, Makoto; Ioka, Tatsuya; Tabernero Caturla, Josep; Oh, Do-Youn (Elsevier, 2023-04)

Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer

Cortellini, Alessio; Aguilar Company, Juan; Salazar, Ramón; Bower, Mark; Sita-Lumsden, Ailsa; Plaja, Andrea (Springer Nature, 2022-11-09)

Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study

Randon, Giovanni ; Nakamura, Yoshiaki; CREMOLINI, CHIARA; Yaeger, Rona; Lonardi, Sara; Elez, Elena; Ros, Javier (American Association for Cancer Research, 2024-01-15)

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

Pascual, Tomás; Antunes de Melo Oliveira, Ana Mafalda; Villagrasa, Patricia; Ortega Cebrian, Vanesa; Bermejo, Begoña; Nuciforo, Paolo Giovanni; Rubio Rodríguez, Isabel Teresa; Cortés Castan, Javier; Paré, Laia (Nature Research, 2021-11-25)

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

Lopez-Bonet, Eugeni; Buxó, Maria; Cuyàs, Elisabet; Pernas, Sonia; Dorca, Joan; Álvarez, Isabel; Cortés Castan, Javier (MDPI, 2019-12-11)

Neratinib in patients with HER2 -mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

Oaknin Benzaquen, Ana Mazaltob; Friedman, Claire F.; Roman, Lynda D.; D'Souza, Anishka; Braña Garcia, Irene; Bidard, François-Clement (Elsevier, 2020-10)

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Antunes de Melo Oliveira, Ana Mafalda; Feng, Yin-Hsun; Dai, Ming-Shen; Chen, Shang-Wen; Hurvitz, Sara; Saura Manich, Cristina (American Society of Clinical Oncology, 2020-09-20)

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

Moy, Beverly; Antunes de Melo Oliveira, Ana Mafalda; Gradishar, William; Kim, Sung‑Bae; Brufsky, Adam; Saura Manich, Cristina (Oxford University Press, 2021-07)

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management

Benitez Hidalgo, Olga; Bescós Cabestre, Agustí; Juarez Giménez, Juan Carlos; Gironella Mesa, Mercedes; Bosch Albareda, Francesc; Martinez Garcia, Maria Fernanda (Wiley, 2022-05)

New Cases and Mutations in SEC23B Gene Causing Congenital Dyserythropoietic Anemia Type II

Musri, Melina Mara; Venturi, Veronica; Ferrer, Xènia; Romero Cortadellas, Lídia; Hernandez Viedma, Gonzalo; Leoz Allegretti, María del Pilar; Beneitez Pastor, David; Ortuño Cabrero, Ana (MDPI, 2023-06-09)

New clinical trial designs in the era of Precision Medicine

Garralda Cabanas, Elena; Piris Giménez, Alejandro; Braña Garcia, Irene; Rodon Ahnert, Jordi; Tabernero Caturla, Josep; Dienstmann, Rodrigo (Wiley Open Access, 2019-01-30)

New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?

Abrisqueta, Pau (MDPI, 2024-03-27)

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA

Gao, Meiling; Callari, Maurizio; Beddowes, Emma; Sammut, Stephen-John; Grzelak, Marta; Biggs, Heather; Cortés Castan, Javier; Antunes de Melo Oliveira, Ana Mafalda (BMC, 2019-01-04)

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

Nowak, Anna K.; Ellingsen, Espen Basmo; Farooqi, Saima Jamil; Bjaanæs, Maria Moksnes; Horndalsveen, Henrik; Cedres Perez, Susana; Haakensen, Vilde Drageset (BMC, 2021-05-31)

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Salmanton‑García, Jon; Marchesi, Francesco; Gomes da Silva, Maria; Davila Valls, Julio; Bilgin, Yavuz M.; Jimenez Balarezo, Moraima; Farina, Francesca (Elsevier, 2023-04)

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Owonikoko, Taofeek; Park, Keunchil; Govindan, Ramaswamy; Ready, Neal; Reck, M.; Peters, S.; Navarro Mendivil, Alejandro (Lippincott Williams & Wilkins, 2021-04-20)

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

Powles, Thomas; Burotto, Mauricio; Escudier, Bernard; Bourlon, Maria T; Shah, Amishi; Apolo, Andrea; Suárez, Cristina (Elsevier, 2024-04-20)

Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer

Goldstein, David; Von Hoff, Daniel D.; Reni, Michele; Tabernero Caturla, Josep; Ramanathan, Ramesh K.; Chiorean, E. Gabriela (Wolters Kluwer Health, 2020-07)

Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer

Chen, Li T.; Macarulla Mercadé, Teresa; Blanc, Jean-Frédéric; Mirakhur, Beloo; Jong, Floris A. de; Belanger, Bruce (MDPI, 2019-07-28)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial

Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer

Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

Neratinib in patients with HER2 -mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management

New Cases and Mutations in SEC23B Gene Causing Congenital Dyserythropoietic Anemia Type II

New clinical trial designs in the era of Precision Medicine

New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer

Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial ﻿

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial ﻿

Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer ﻿

Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study ﻿

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial ﻿

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer ﻿

Neratinib in patients with HER2 -mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial ﻿

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial ﻿

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens ﻿

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management ﻿

New Cases and Mutations in SEC23B Gene Causing Congenital Dyserythropoietic Anemia Type II ﻿

New clinical trial designs in the era of Precision Medicine ﻿

New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes? ﻿

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA ﻿

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma ﻿

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry ﻿

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 ﻿

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial ﻿

Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer ﻿

Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial

Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer

Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

Neratinib in patients with HER2 -mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management

New Cases and Mutations in SEC23B Gene Causing Congenital Dyserythropoietic Anemia Type II

New clinical trial designs in the era of Precision Medicine

New Insights into First-Line Therapy in Diffuse Large B-Cell Lymphoma: Are We Improving Outcomes?

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer

Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer